Jeon Hwa-seong Morning Coffee Ep. 1124: L&P Solution's Growth Secret

Lighthouse of the Startup Ecosystem: L&P Solution, an Innovative Company Met at 'Startup Morning Coffee' Every morning at 8:40 AM, YouTube channel 'Jeon Hwa-sung's CNTV' injects fresh vitality into the startup ecosystem through its 'Startup Morning Coffee' live broadcast. Under the moderation of CEO Jeon Hwa-sung, this program not only deeply illuminates the core competencies and market potential of various startups but also firmly establishes itself as an interactive platform that provides valuable information to viewers through real-time comment communication. The company that has recently drawn attention in this open forum for communication is L&P Solution, which is opening the future of new drug development. L&P Solution: AI Innovation Resolving Inefficiencies in New Drug Development L&P Solution has established its unique new drug research platform called 'LNP AI Smart Bench Platform' to innovatively resolve the immense time and cost inefficiencies that arise during the new drug development process. This platform plays a crucial role throughout the entire process, from the discovery of new drug candidates to the clinical trial stages, contributing to significantly shortening development time and costs. Currently expanding its potential further through CNTTECH's Gangwon K-Camp support program, L&P Solution is opening new horizons in the bio-industry. L&P Solution's Unique Competitiveness Born from Technology Convergence L&P Solution's core competitiveness lies in the sophisticated convergence of computer simulation, molecular modeling, and artificial intelligence (AI) technologies. By integrating AI with computer-aided design (CAD) and molecular modeling techniques, it enables optimal compound design and increases the success rate of new drug development. In particular, its unique technology that predicts the potential toxicity of compounds in advance using deep learning models significantly reduces trial and error during the development process. Thus, AI-based molecular modeling acts as a crucial factor in maximizing the overall efficiency of new drug development by providing researchers with a one-stop decision-making system. L&P Solution Promises Continuous Growth and a Bright Future CEO Jeon Hwa-sung was deeply impressed by L&P Solution's exceptional expertise. The synergy between the founder, who possesses excellent sales capabilities in the field of molecular modeling, and the CTO and research team, composed of AI-based new drug development experts, is a powerful growth driver for this company. Indeed, L&P Solution achieved sales of 1.2 billion won last year and is continuing its steady growth, targeting approximately 1.5 billion won this year. L&P Solution's innovative new drug research platform, which generates stable revenue based on its software and B2B (business-to-business) model, is expected to establish itself as an indispensable and important player in the future bio-industry.